Hikma Sticks to 2026 Guidance as Divisions Deliver in Q1
Hikma Pharmaceuticals has reconfirmed its full-year 2026 guidance after first-quarter results that met management expectations across its Injectables and US Rx divisions. The Injectables business stayed on track for low single-digit revenue growth and a 27% to 28% core operating margin, supported by strong US demand for Tyzavan and ongoing capacity…